By Christian Moess Laursen

Novartis said Wednesday that Sandoz has agreed to enter a partnership with Seattle-based Evotec subsidiary Just-Evotec Biologics to develop and manufacture biosimilar medicines.

The Swiss pharma major said the multiyear partnership agreement covers the development and manufacture of several biosimilar medicines and includes an option for expansion.

The partnership supports Sandoz's pipeline expansion to 24 biosimilar assets, as development of the biosimilars will ramp up over the coming 12-18 months, the company said.

Novartis said the agreement is the most recent step toward solidifying Sandoz' foundation as a standalone company.

Write to Christian Moess Laursen at christian.moess@wsj.com

(END) Dow Jones Newswires

May 10, 2023 01:52 ET (05:52 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Novartis.